Good news! Jiudian Hongyang’s pharmaceutical excipient, Sodium Hydrogen Phosphate Heptahydrate (F20210000322), has recently been approval by the National Medical Products Administration (NMPA). Its registration status has successfully transitioned from "I" to "A," making it the first product of its kind. This will provide crucial support for the research and development, as well as the production, of pharmaceutical formulations.

Sodium Hydrogen Phosphate Heptahydrate is used as an excipient in various medications, suitable for a wide range of dosage forms. It plays an essential role in pharmaceutical formulations. It is commonly used as a pH regulator, buffer, and osmolality modulator in injection solutions, eye drops, tablets, and capsules. By regulating pH levels and osmolality, as well as providing buffering effects, Sodium Hydrogen Phosphate Heptahydrate can effectively prevent hydrolysis, oxidation, and other reactions during storage and use, ensuring the stability and efficacy of the medication. Additionally, it adjusts the pH and osmolality to levels compatible with the human body’s physiological environment, reducing irritation to the body, lowering the risk of adverse reactions, and improving the safety of the medication.

The approval of Sodium Hydrogen Phosphate Heptahydrate marks a milestone breakthrough, not only filling a domestic market gap but also meeting the increasing demand for pharmaceutical formulation production in China. It also signals that our company has reached a new height in the pharmaceutical excipient industry. Jiudian Hongyang will continue to invest in the research and development of pharmaceutical excipients, constantly improving product quality and service levels, and building a competitive platform for raw materials and excipients to make a greater contribution to the development of China’s pharmaceutical industry.